Status:
UNKNOWN
Effects of Vildagliptin Versus Glibenclamide on Glycemia After Exercise in Patients With Type 2 Diabetes
Lead Sponsor:
Hospital de Clinicas de Porto Alegre
Conditions:
Diabetes Mellitus, Type 2
Hypoglycemic Agents
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Exercise is considered a way to benefit the health of unhealthy and healthy individuals. This is confirmed by different scientific researches, in which people who participated improve their health. Th...
Detailed Description
The main procedures will occur during three consecutive days, before randomization and 3 days before 12 weeks. In the first day, the patients will begin the 24hour urinary collection; the ultrasonogra...
Eligibility Criteria
Inclusion
- Type 2 diabetes (fasting glucose ≥ 126 mg/dl or 7.0 mmol/l)(25);
- Recent HbA1C determination (between 7, 5 and 10%);
- Not involved in regular physical exercise;
- Older than 18 years;
- In use of Metformin.
Exclusion
- Smoker and use of analgesic or anti-inflammatory drugs during the week of the study
- BMI \> 40 kg/m²;
- Proliferative retinopathy;
- Ischemic cardiomyopathy;
- Peripheral vascular disease;
- Blood Aspartate transaminase (AST) and Alanine transaminase (ALT) 2.5 times higher the normal concentration before screening visit
- Lactose intolerance;
- Renal insufficiency (creatinine clearance \<60ml/min);
- Blood pressure more than 180/100mmHg at rest (3 consecutive measures).
Key Trial Info
Start Date :
April 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2015
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT01867502
Start Date
April 1 2014
End Date
August 1 2015
Last Update
May 6 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital de Clínicas de Porto Alegre Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil, 90035-903